Phosphodiesterase4D (PDE4D) — A risk factor for atrial fibrillation and stroke?
- 1 December 2015
- journal article
- review article
- Published by Elsevier in Journal of the Neurological Sciences
- Vol. 359 (1-2) , 266-274
Abstract
No abstract availableKeywords
Funding Information
- Herlev Hospital
- Lundbeck Foundation
This publication has 98 references indexed in Scilit:
- Cryptogenic Stroke and Underlying Atrial FibrillationNew England Journal of Medicine, 2014
- Global and regional burden of stroke during 1990–2010: findings from the Global Burden of Disease Study 2010The Lancet, 2014
- The economic cost of brain disorders in EuropeEuropean Journal of Neurology, 2011
- Variation in the PDE4D Gene and Ischemic Stroke RiskStroke, 2008
- cAMP-Specific Phosphodiesterase-4 Enzymes in the Cardiovascular SystemCirculation Research, 2007
- Cyclic Nucleotide Phosphodiesterases: Molecular Regulation to Clinical UsePharmacological Reviews, 2006
- Phosphodiesterase 4D polymorphisms and the risk of cerebral infarction in a biracial population: the Stroke Prevention in Young Women StudyHuman Molecular Genetics, 2006
- Cyclic nucleotide phosphodiesterase (PDE) superfamily: A new target for the development of specific therapeutic agentsPharmacology & Therapeutics, 2006
- The gene encoding phosphodiesterase 4D confers risk of ischemic strokeNature Genetics, 2003
- Classification of subtype of acute ischemic stroke. Definitions for use in a multicenter clinical trial. TOAST. Trial of Org 10172 in Acute Stroke Treatment.Stroke, 1993